|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||19.02 - 20.39|
|52 Week Range||5.55 - 31.85|
|Beta (5Y Monthly)||1.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.04|
By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT On March 9, 2021, DarioHealth Corp. (NASDAQ:DRIO) announced its fourth quarter and FY:20 operational and financial results and filed its form 10-K. 2020 marked a transformative year for Dario as it maneuvered towards a B2B2C-oriented strategy, winning three major accounts in the last several months, including two Fortune 500 companies and one of the largest integrated healthcare systems in New Mexico. Over the last year, Dario added to its management team, appointed new members to its Scientific Advisory Board and presented results from a study showing efficacy of Dario’s platform in glucose readings in diabetic adults over 65. Following the reporting period, Dario acquired Upright Technologies, an early-stage app-and-device based platform in the musculoskeletal (MSK) space. The new addition was consummated in a mostly stock deal and addresses posture and other MSK conditions, expanding Dario’s offerings in
DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the fourth quarter and full year 2020 and provided a corporate and commercial update.
NEW YORK, NY / ACCESSWIRE / March 9, 2021 / DarioHealth Corp. (NASDAQ:DRIO) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 9, 2021 at 8:30 AM Eastern Time.